News Hub | News Direct

Alberta Becomes the First Province to Regulate Psychoactives for Therapeutic Purposes

MarketJar

The modern psychoactive renaissance is continuing to gain momentum, with Alberta becoming the latest region to propose regulatory changes regarding the substances. On October 5, Government officials declared that Alberta will be the first province in Canada to regulate psychoactives for the treatment of psychiatric disorders. Although doctors and researchers are allowed to apply to Health Canada for permission to use psychoactives in clinical research or grant patients special access for therapeutic use, they are still illegal in Canada. According to Alberta's new laws, medical professionals must submit an application to the province for a license before administering psychoactives to patients with mental illnesses. Alberta's new laws governing the therapeutic use of psychoactives are expected to take effect on January 16, 2023. At a time when the mental health crisis is getting worse and more people are turning to alternative treatment providers for assistance, these regulatory changes are timely. According to John Hopkins Medicine, over 6.7 million people in Canada experience mental illnesses, compared to 26% of Americans age 18 and older who experience a diagnosable mental disorder each year. Psilocybin has recently attracted renewed interest as a potential treatment for conditions like anxiety, addiction, and depression. And these recent changes to the law demonstrate the legitimacy of psychoactive-assisted therapy within the health care system. Companies in the market stand to gain as psychoactives become more accepted, especially those that provide high-quality goods and integrated mental health care treatment options at clinics. The development and provision of cutting-edge mental health care and access to secure, scientifically supported psychoactive-assisted therapies are the main priorities of Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF), a leading provider of integrated mental healthcare. The range of mental health services Numinus offers and its network of wellness centers across Canada and the US have kept growing. One of the reasons behind Numinus ’ ongoing growth is its growth-focused strategy. Over the last couple of years, the company has made several sizable acquisitions that have directly contributed to its bottom line. In 2021, Numinus added Neurology Centre of Toronto and Mindspace to the company, both of which are responsible for the notable uptick in revenue in the past year. Then in June 2022, the company completed the acquisition of Novamind, along with its network of wellness clinics, bringing its total network to 12 wellness clinics, four research facilities and a dedicated psychoactives research lab. On November 29, Numinus announced its Q4 and full year results, revealing a 643% increase in fourth quarter revenue thanks to the acquisition of Novamind. The company reported C$4.2 million in revenue for Q4, $3.7 million of which came from its wellness clinic network. Numinus also grew its gross margin to 31.5% in the fourth quarter, generating $1.3 million in gross profit and ended the quarter with a $33 million cash position. “Fiscal 2022 was a pivotal year for Numinus, as we entered the US market with the transformational acquisition of Novamind, expanded our Ketamine-assisted Therapy offering across Canada, launched a formal practitioner training program, and unveiled a global rebranding of our company. Combined, these efforts have provided a solid platform for our continued, measured growth – with scalable infrastructure and systems, and a growing pipeline of practitioners choosing Numinus for their psychedelics-assisted therapy training,” said Payton Nyquvest, Founder and CEO of Numinus. “With our strong wellness clinic network and a growing clinical research division, Numinus is one of the best positioned companies in the sector – supported by diversified revenue streams, growing brand awareness, and a recognized pathway to profitability.” Commenting on the quarter, Nyquvest continued: “Our fiscal fourth quarter was the first to demonstrate the real power of our larger, cross-border platform following the acquisition of Novamind on June 10, 2022 – and the impacts are evident in our performance. Compared to the previous quarter, fourth quarter revenues grew 464% to $4.2 million, gross margin improved by 710 basis points from 6.5% to 31.5%, and gross profit grew 628% to $1.3 million. We’re excited about the momentum building across our business and the regulatory reform underway across the US and Canada, and will continue to evaluate complementary growth opportunities that will enhance our client experience and further support margin expansion.” During Q4 2022, Numinus completed over 17,000 client appointments, which represents a 202% increase in clinic appointments compared to over 5,600 appointments in Q3 2022, mostly due to the acquisition of Novamind at the beginning of the quarter. Numinus acquired Novamind in June 2022, along with its network of wellness clinics. This brings its total network to 13 wellness clinics, four research facilities and a dedicated psychoactives research lab. And this is just the beginning of what this company plans to achieve. To learn more about Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF) and how it is pioneering the integration of psychoactive-assisted therapies into standard clinical practice, click this link or visit the company’s website Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Numinus Wellness Inc. Market Jar Media Inc. has or expects to receive from Numinus Wellness Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) one hundred nine thousand four hundred and forty USD for 23 days (16 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Numinus Wellness Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Numinus Wellness Inc.’s industry; (b) market opportunity; (c) Numinus Wellness Inc.’s business plans and strategies; (d) services that Numinus Wellness Inc. intends to offer; (e) Numinus Wellness Inc.’s milestone projections and targets; (f) Numinus Wellness Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Numinus Wellness Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Numinus Wellness Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Numinus Wellness Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Numinus Wellness Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Numinus Wellness Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Numinus Wellness Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Numinus Wellness Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Numinus Wellness Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Numinus Wellness Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Numinus Wellness Inc.’s business operations (e) Numinus Wellness Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Numinus Wellness Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Numinus Wellness Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Numinus Wellness Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Numinus Wellness Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Numinus Wellness Inc. or such entities and are not necessarily indicative of future performance of Numinus Wellness Inc. or such entities.. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

November 30, 2022 07:30 AM Pacific Standard Time

Image

New York Issues First 36 Licences for Recreational Cannabis Dispensaries

MarketJar

Over the past ten years, the legal cannabis market in North America has advanced significantly. Another 20 states have joined the movement since Colorado made history by legalizing recreational marijuana in 2012, and several more may soon do the same. On November 21, New York took a monumental step in establishing a legal and lucrative marketplace for recreational marijuana by issuing its first 36 dispensary licenses. The majority of the businesses are owned by people who have been disproportionately impacted by the drug war, while others are run by nonprofit organizations. The licenses approved by the state's Cannabis Control Board were the first of 175 that the state intends to issue, with many of the first round reserved for applicants with prior cannabis-related convictions. Even though the licensing program was being challenged in court, the state Cannabis Control Board voted to give licenses to 28 entrepreneurs and eight nonprofits. This will complete a supply chain from seed to sale, which should allow legal sales to start in the state. The goal of the licensing process was to help the state reach its goal of giving people from underserved areas priority for jobs in the legal cannabis industry. Even though people of all races used marijuana at about the same rate, marijuana prohibition in New York and the rest of the country mostly brought Black and Latino people into the criminal justice system. In March of 2018, New York made it legal for adults to use cannabis for fun. This meant that each person could have up to three ounces of weed or 24 grams of concentrate. Officials say that sales will start in stores before the end of 2022. In the first round, businesses and organizations competed for 175 licenses, which let operators open up to three dispensaries. Most of them, about 150, are expected to go to businesses that the state will help open by renting them turnkey spaces and giving them loans to cover the cost of getting their storefronts ready. The last 25 licenses are set aside for organizations that help people in need. The number of cannabis products available on the market is growing as more states legalize marijuana for recreational purposes. The three-pillar business plan of Flora Growth Corp. (NASDAQ:FLGC), a next-generation cannabis firm with a focus on commercial wholesale, consumer brands, and life sciences, makes it unique in the market. For the diverse applications of cannabis and other plant-based products, Flora Growth creates a wide variety of brands and services. The business has operations in multiple countries and diversified revenue streams. Flora Growth Reports Another Record Quarter Flora Growth has continued to achieve positive revenue growth in 2022. On November 28, the company reported Q3 2022 revenue of US$10.8 million, a 414% increase from the previous year and $25.7 million in revenue for the first nine months of 2022, which represents an increase of 510% year-over-year (YoY). The revenue increase is primarily attributed to acquired brands, JustCBD and Vessel. Flora Growth also increased its gross profit by approximately 703% YoY to approximately $5.0 million. “The third quarter of 2022 was another exciting quarter for Flora as we continued to lay the foundation of our business for the long-term, ” said Flora Growth Chairman and CEO Luis Merchan. “During the quarter, we exported products to several new markets, including distribution of our Colombian grown dried flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States. Our global distribution network, coupled with our high-quality Colombian flower and derivatives, leave Flora well positioned to capitalize on the evolving global cannabis landscape.” Additionally, Flora Growth reaffirmed that it is on track to generate $35 to 45 million in revenue in 2022. To learn more about Flora Growth Corp (NASDAQ:FLGC), please click this link or visit the company’s website. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Flora Growth Corp. Market Jar Media Inc. has or expects to receive from Flora Growth Corp’s Digital Marketing Agency of Record (Native Ads Inc.) nineteen thousand USD for 7 days (5 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Flora Growth Corp.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Flora Growth Corp.’s industry; (b) market opportunity; (c) Flora Growth Corp.’s business plans and strategies; (d) services that Flora Growth Corp. intends to offer; (e) Flora Growth Corp.’s milestone projections and targets; (f) Flora Growth Corp.’s expectations regarding receipt of approval for regulatory applications; (g) Flora Growth Corp.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Flora Growth Corp.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Flora Growth Corp.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Flora Growth Corp.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Flora Growth Corp.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Flora Growth Corp.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Flora Growth Corp. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Flora Growth Corp.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Flora Growth Corp.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Flora Growth Corp.’s business operations (e) Flora Growth Corp. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Flora Growth Corp. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Flora Growth Corp. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Flora Growth Corp. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Flora Growth Corp. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Flora Growth Corp. or such entities and are not necessarily indicative of future performance of Flora Growth Corp. or such entities. Contact Details Market Jar Media Inc. James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

November 30, 2022 06:30 AM Pacific Standard Time

Image

CORRECTION: Expansion of Pipeline to Mental Health

The Chicago School of Professional Psychology

Nearly half of U.S. psychologists in a new survey say they cannot meet the growing demand for services and three-quarters say they have longer waiting lists than before the pandemic. “This new survey confirms what we have already heard from patients: people are having a hard time accessing the mental health services they need,” said Dr. Michele Nealon, Psy.D., President of The Chicago School of Professional Psychology. “It is critical now more than ever to expand the pipeline for mental health professionals and promote integrated behavioral health into primary care.” The 2022 COVID-19 Practitioner Impact Survey of almost 2,300 psychologists by the American Psychological Association found that demand for treatment of anxiety and depression remained high for the third consecutive year, along with increased demand for treatment of stressor-related disorders, and substance use disorders. Six in 10 practitioners said they had no more openings for new patients, nearly half (46%) said they had been unable to meet treatment demand and nearly three quarters (72%) have longer waiting lists than before the pandemic. On average, psychologists reported being contacted by more than 15 potential new patients seeking care per month. Nearly eight in 10 psychologists (79%) said they had seen an increase in the number of patients with anxiety disorders since the start of the pandemic, and 66% had seen an increase in the demand for treatment for depression. Almost half (47%) said they had seen an increase in demand for substance use treatment (compared to 43% last year) and 64% had seen an increase in demand for trauma treatment (compared to 62% last year). 2021). Additionally, two-thirds of psychologists reported seeing an increase in symptom severity among patients in 2022. “The social, emotional, and economic effects of a pandemic are still with us and will be for quite some time. In addition, the stressors associated with inflation, social and racial inequities, political upheaval, and international tensions are creating an unsettled nation. At a time when mental health services are needed the most, we are struggling the most to meet those needs,” said Dr. Nealon. “Policy makers have to make a bigger investment in financial and programmatic support to ensure that everyone who seeks psychological services can find a professional who can understand and help them.” The Chicago School of Professional Psychology is a non-profit majority minority institution, educating 6,000 students at seven campuses in major metro areas around the national. Two of three identify as students of color, including a significant number of first-generation college students. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

November 29, 2022 06:18 PM Eastern Standard Time

Induction Healthcare Group focused on "building out core capability"

Induction Healthcare Group PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 29, 2022 07:00 AM Eastern Standard Time

Video

Expansion of Pipeline to Mental Health

The Chicago School of Professional Psychology

Nearly half of U.S. psychologists in a new survey say they cannot meet the growing demand for services and three-quarters say they have longer waiting lists than before the pandemic. “This new survey confirms what we have already heard from patients: people are having a hard time accessing the mental health services they need,” said Dr. Michele Nealon, Psy.D., President of The Chicago School of Professional Psychology. “It is critical now more than ever to expand the pipeline for mental health professionals and promote integrated behavioral health into primary care.” The 2022 COVID-19 Practitioner Impact Survey of 2,300 psychologists by the American Psychological Association found that demand for treatment of anxiety and depression remained high for the third consecutive year, along with increased demand for treatment of trauma-related disorders, increased stressors, and substance use disorders. Six in 10 practitioners said they had no more openings for new patients, nearly half (46%) said they had been unable to meet treatment demand and nearly three quarters (72%) have longer waiting lists than before the pandemic. On average, psychologists reported being contacted by more than 15 potential new patients seeking care per week. Nearly eight in 10 psychologists (79%) said they had seen an increase in the number of patients with anxiety disorders since the start of the pandemic, and 66% had seen an increase in the demand for treatment for depression. Almost half (47%) said they had seen an increase in demand for addiction treatment (compared to 43% last year) and 64% had seen an increase in demand for trauma treatment (compared to 62% last year). 2021). Additionally, two-thirds of psychologists reported seeing an increase in symptom severity among patients in 2022. “The social, emotional, and economic effects of a pandemic are still with us and will be for quite some time. In addition, the stressors associated with inflation, social and racial inequities, political upheaval, and international tensions are creating an unsettled nation. At a time when mental health services are needed the most, we are struggling the most to meet those needs,” said Dr. Nealon. “Policy makers have to make a bigger investment in financial and programmatic support to ensure that everyone who seeks psychological services can find a professional who can understand and help them.” About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Kelton Gibson +1 661-607-2012 kgibson1@thechicagoschool.edu

November 28, 2022 10:55 AM Pacific Standard Time

The “Cannabis Science Fair” to Showcase Cannabis Research & Innovation

MCR Labs

Local cannabis testing leader MCR Labs is partnering with the Cannabis Center of Excellence (CCoE) to host the “Cannabis Science Fair.” The event returns for its second year to show off the important work major academic and commercial institutions are conducting to further our knowledge of cannabis. The fair, which is free and open to the public, will feature poster presentations and speakers from academic institutions like Harvard and companies like Biomerieux and Smokenol. “After such a great response last year, we are stoked to present new, exciting research and innovation at this year’s fair,” said Melissa Kenton, MCR Lab’s Events & Outreach Manager and the main organizer behind the event. “There is a huge demand and curiosity for more information on cannabis, and we are happy to provide a venue for professionals in the field to share their knowledge.” MCR Labs provides product compliance testing to licensed cannabis producers, but advancing research efforts is also an important part of the company’s mission. Several of the company’s scientists will be there showcasing the research they’ve conducted on topics ranging from the effects of growing environment on cannabis to the relationship between phosphorus and arsenic in the plant. Dr. Staci Gruber, Director of Marijuana Investigations for Neuroscientific Discovery (MIND) Program at McLean Hospital, will be giving the first keynote presentation of the day titled “What to Keep in MIND: Recreational vs. Medical Cannabis.” Jeff Rawson, a Harvard Postdoctoral Fellow, will give the second talk of the day titled “Is Misinformation Common in Cannabis Markets?” “The Cannabis Science Fair” will be held at the Harvard University Science Center on Saturday, Dec. 3 from 11a.m to 5 p.m. Anyone interested in learning more or attending the event can find details on the event website. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

November 28, 2022 10:49 AM Eastern Standard Time

Image

C4X Discovery signs potential $402mln deal

C4X Discovery Holdings PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 28, 2022 09:30 AM Eastern Standard Time

Video

This Electric Toothbrush Has Received A 90% Five-Star Review Rating. What Is Making It A Favorite Of Nick Jonas, Kevin Hart And Others?

Bruush Oral Care Inc.

These days when a buyer visits any well-known e-commerce websites such as Amazon.com Inc. (NASDAQ: AMZN), eBay Inc. (NASDAQ: EBAY), Walmart Inc. (NYSE: WMT) or Target Corporation (NYSE: TGT) to buy a product, they are often likely to look at the reviews and ratings of the product before making the purchase. In this fast-evolving digital age, studies have shown that 93% of consumers say online reviews impact their purchase decision. In comparison, 94% also said an online review has convinced them to avoid a business. With dozens of similar products on offer nowadays, most customers easily overlook businesses or products with bad reviews or ratings. Having a solid reputation score or positive review can ultimately lead to high sales, and this seems to be a part of the success story of Brüush Oral Care Inc. (NASDAQ: BRSH). With 83% of Gen Z and millennials reporting that they trust online reviews as much as personal recommendations, Brüush’s five-star reviews can surely help sway some consumers to try out this electric toothbrush. The company boasts that its beautifully designed one-of-a-kind electric toothbrush has received more than 90% five-star review ratings with less than a 1% return rate. For comparison, the overall merchandise return rate for U.S. retail sales was slightly over 10% in 2020. From the ratings, one could conclude that Brüush is a favorite of many, including millennials and celebrities. Raving Reviews Interestingly, not only regular customers are giving raving reviews of the company’s electric toothbrush, but also celebrities. Celebrities, including singer, songwriter and actor Nick Jonas as well as comedian and actor Kevin Hart are huge fans and users. “Not just a toothbrush. My wife (Priyanka Chopra) and I both use this - we’re obsessed, and we’ve gifted this to a lot of friends because it’s just the best toothbrush I’ve ever owned, and I’ve owned a lot of toothbrushes,” Nick Jonas told GQ magazine. After trying the company’s toothbrush himself — and loving it — Kevin Hart joined Brüush’s mission to elevate self-confidence through cleaner, whiter teeth — making people laugh along the way. With Nick Jonas, Kevin Hart and millennials giving rave reviews to this brush, is it time to replace your old toothbrush(es) with Brüush? Brushing Out The Competition Built with the highest-quality Sonicare technology, four-week battery life and best-in-class prices, Brüush says it is determined to make a move from manual a no-brainer backed by a brush head refill subscription plan. The plan includes three new brush heads for $18 ($6 per brush head) with free shipping every six months. “We set out to create a better electric toothbrush to make maintaining your teeth easy. We fused industry-leading sonic technology with six cleaning modes and ultra-soft bristles for an effective clean that’s always gentle on your gums. Plus, with our easy refill plan, you’ll never overspend on or forget to change your brush head again,” Brüush said on its website. Apart from the industry-leading technology and high performance, another unique selling point of Brüush could be its standout design language. “The design-forward toothbrush is complemented by new seasonal colors, a vibrant brand personality and exciting collaborations.” To win in today’s physical and digital marketplace, companies are paying closer attention to the needs of millennials, who seem to have a strong connection to colors. From eclipse black to cloud white, blush pink or even tiffany blue, Brüush offers several color options for customers, including millennials who favor bright and energetic colors. Packaging and strong product quality are likely significant contributors to why consumers and celebrities alike love the products, and why they may continue to grow in the oral health sector with other big players like Procter & Gamble Co. (NYSE: PG), Koninklijke Philips NV (AMS: PHIA), and Quip. Learn more about Brüush by downloading the latest research report here About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

November 28, 2022 09:10 AM Eastern Standard Time

Retention Cloud Leader CleverTap Launches CleverTap for Startups

CleverTap

CleverTap, the modern, integrated retention cloud today announced the launch of CleverTap for Startups (C4S). Through this initiative, CleverTap will offer a full stack retention platform to all budding digital-native brands, in order to help them personalize and optimize all customer touchpoints, improving user engagement and conversion. Till date, thousands of large digital-native brands have benefited from CleverTap’s platform which has solved their needs at scale, speed, and security. The aim now is to make solutions even more affordable for pre-launch, early-stage startups, or companies with limited monthly active users. New and early-stage businesses have very different needs from larger, well-established brands. They require more flexibility, affordability, and a partner that provides seamless support fuelling their growth plans. CleverTap has currently partnered with more than 50 venture capital firms, incubators, and business accelerators including Sequoia Surge, Techstars, Y-combinator, AWS Activate, Accel and others to provide exclusive discounts and resources to early-stage startups through this initiative. The C4S initiative was undertaken a year back and the offerings have now been fine tuned following feedback from 1000+ startups and is now ready to launch. Through this initiative, CleverTap aspires to be a growth partner for more than 100,000 new businesses by the end of 2025. Through this initiative, early stage startups can opt for a flexible plan with no minimum scale requirement, and can make use of the platform with as low as 5000 monthly active users. The platform is designed realizing the requirement of SMBs/startups. Additionally, customers will have the option to customize the platform with add-ons and will have the ability to only pay for the services they use. Speaking about the initiative Anand Jain, Co-Founder & Chief Product Officer, CleverTap said, “Every small business needs an ecosystem of stakeholders that are supportive and will help them get on their growth journeys. Be it small or big, startups can use all the help they can get. In our effort to bolster new businesses globally we are excited to launch CleverTap for Startups. Customer retention for consumer brands is one of the key components to building a successful business. By offering our solutions to startups at a lower cost with flexible options, we want to create an atmosphere where we can support new businesses from their 0 to 1 and then 1 to 100 journeys.” About CleverTap CleverTap is the World's #1 Retention Cloud that helps app-first brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ - the world’s first purpose-built database for customer engagement, offering both speed and economies of scale.CleverTap is trusted by 1500 customers, including Gojek, ShopX, Electronic Arts, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details CleverTap Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

November 25, 2022 08:22 AM Eastern Standard Time